FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to gastroenterology, internal diseases and laboratory diagnostics, and can be used for diagnosing hepatic steatosis in women with overweight or obesity in postmenopausal women by means of blood analysis. Patient’s blood serum is examined for the level of leptin by enzyme immunoassay. If the blood serum leptin value is 13 ng/ml and more, the presence of hepatic steatosis is diagnosed in overweight or obese postmenopausal women. If the leptin level is less than 13 ng/ml, there is no hepatic steatosis.
EFFECT: method provides the possibility of reducing injuries, accessibility and simplicity of implementation with high sensitivity and specificity due to determination of leptin level in blood.
1 cl, 1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR DIAGNOSING NON-ALCOHOLIC HEPATIC STEATOSIS IN MENOPAUSAL WOMEN | 2022 |
|
RU2785905C1 |
| METHOD FOR DIAGNOSING NON-ALCOHOLIC HEPATIC STEATOSIS | 2021 |
|
RU2755974C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME WITH VITAMIN D DEFICIENCY | 2018 |
|
RU2694842C1 |
| METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANYING METABOLIC SYNDROME | 2018 |
|
RU2686042C1 |
| METHOD OF DETERMINING THE RISK OF SEVERE LIVER STEATOSIS | 2023 |
|
RU2806496C1 |
| METHOD FOR PREDICTING MACROSOMIA IN PREGNANT WOMEN WITH ANDROID-TYPE OBESITY IN THE FIRST TRIMESTER OF PREGNANCY | 2021 |
|
RU2779994C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF STEATOSIS AND NON-ALCOHOLIC STEATOHEPATITIS IN FEMALES | 2020 |
|
RU2744021C1 |
| METHOD OF CHOOSING THERAPEUTIC APPROACH IN MENSTRUAL DISORDERS IN ADOLESCENT GIRLS WITH OVERWEIGHT | 2010 |
|
RU2422824C1 |
| MINIMALLY INVASIVE METHOD FOR DIAGNOSING NON-ALCOHOLIC FATTY LIVER DISEASE BASED ON THE IDENTIFICATION OF MIRNAS AND MIP-1β IN BLOOD PLASMA | 2022 |
|
RU2798163C1 |
| METHOD FOR SELECTING THERAPEUTIC APPROACH TO FEMALE PATIENTS WITH OLIGOMENORRHEA AND OBESITY | 2014 |
|
RU2555347C1 |
